Expanding clinical-stage microbiome therapeutic pipelines and the need for specialized anaerobic manufacturing are increasing demand for contract development and manufacturing services, according to Fact.MR.
NEWARK, Del., October 12, 2026. The global live biotherapeutic products and microbiome contract development and manufacturing organization (CDMO) market is projected to reach USD 1,444.1 million by 2036, up from USD 104.0 million in 2026, according to Fact.MR. The market is forecast to expand at a compound annual growth rate (CAGR) of 30.1% from 2026 to 2036, creating an absolute dollar opportunity of approximately USD 1.3 billion over the forecast period.
The market covers specialized contract services for therapeutic products containing defined live microbial strains. These services include strain isolation and development, anaerobic fermentation, formulation, fill-finish operations and analytical testing under good manufacturing practice (GMP) conditions.
Get detailed market forecasts, competitive benchmarking, and pricing trends:
Clinical development is increasing demand for specialized manufacturing
Microbiome therapeutic development is creating a need for manufacturing capabilities that many pharmaceutical sponsors do not maintain internally. Fact.MR identifies expanding clinical pipelines across gastrointestinal, oncology and immunology indications as a central demand driver.
Manufacturing live microbial products requires specialized infrastructure and process controls. Anaerobic production, microbial viability throughout formulation and distribution, and analytical testing can create technical barriers for developers using conventional manufacturing facilities.
Regulatory pathway clarity from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is another factor identified in the report. The report summary, however, does not specify individual regulations, document titles, publication dates or compliance deadlines. No particular regulatory change is therefore attributed as the immediate trigger for market growth in this release.
Where growth is fastest
Fact.MR forecasts strong expansion across the seven country markets listed in its report.
- China: The market is projected to grow at a CAGR of 44.9% through 2036, the highest rate among the countries profiled. Fact.MR identifies expanding end-use demand and investment in infrastructure as supporting factors.
- India: Growth is forecast at 42.7% CAGR, supported in the report’s country outlook by expanding demand and adoption of higher-specification products.
- United States: The market is expected to expand at 40.2% CAGR. Fact.MR identifies regulatory-driven procurement and technology adoption among the factors supporting demand.
- United Kingdom: Growth is projected at 38.9% CAGR, reflecting the report’s outlook for the European market.
- Germany: The market is forecast to grow at 37.6% CAGR through 2036.
- Japan: Fact.MR projects a CAGR of 36.1%.
- Brazil: The market is expected to expand at 34.4% CAGR over the forecast period.
These are forecast growth rates, not realized annual results. The report summary provides limited country-specific evidence, so the rates should not be interpreted as proof of particular government initiatives, clinical milestones or manufacturing investments.
What leads the market?
The report summary lists the following leading segments for 2026:
- Product: Antimicrobial Surgical Products, with a reported 54% share.
- Application: Orthopedic Surgeries, with a reported 58% share.
- End use: Hospitals, with a reported 46% share.
Editorial qualification: These segment labels do not clearly align with the report’s stated scope of live biotherapeutic products and microbiome CDMO services. They require confirmation from Fact.MR before publication and should not be treated as validated market shares for microbiome manufacturing.
The hurdle: Limited qualified manufacturing capacity
The availability of specialized manufacturing facilities is a key constraint. Fact.MR identifies the limited number of CDMOs with anaerobic GMP capabilities as a source of potential capacity bottlenecks during periods of strong clinical demand.
Maintaining microbial viability across manufacturing, formulation and distribution adds another layer of operational complexity. Developers must also account for uncertainty in early-stage clinical programs: some candidates may not progress to commercial production, creating uncertainty around future manufacturing volumes and capacity utilization.
For CDMOs, these factors make technical qualification, process consistency and the ability to support complex microbial products important considerations when evaluating capacity expansion.
Industry investment and competitive outlook
Fact.MR identifies three areas of opportunity: manufacturing demand following the first commercial approvals of live biotherapeutic products, higher-value contracts for multi-strain consortium products, and geographic expansion of CDMO capacity into Asia Pacific.
The report does not provide dated, verifiable company announcements or individual product-development milestones in its accessible summary. Accordingly, no company-specific investment, partnership, acquisition or regulatory approval is presented here as a recent development.
The companies profiled in the report are:
Lonza Group Ltd; Arrant Bioscience (Arrant Bio); 4D Pharma plc; Cerbios-Pharma SA; Biose Industrie; Assembly Biosciences, Inc.; Wacker Chemie AG; Quay Pharmaceuticals Ltd.; NIZO Food Research B.V.; and Inpac Pharma Co., Ltd.
Their inclusion indicates that they are covered in the report; it does not imply that each company has announced a new investment or is pursuing an identical commercial strategy.
Analyst perspective
Shambhu Nath Jha, Principal Consultant at Fact.MR, said:
“The live biotherapeutic CDMO market is at an inflection point where clinical pipeline expansion is outpacing available manufacturing capacity. Most pharmaceutical sponsors cannot produce live biotherapeutics in-house because anaerobic GMP manufacturing requires specialized equipment, facility design, and operational expertise that differs fundamentally from conventional biologic or small molecule production. This creates a structural outsourcing dynamic where CDMO demand grows in proportion to clinical pipeline activity. Companies with established anaerobic manufacturing infrastructure, regulatory filing experience, and the ability to handle multi-strain consortium products are capturing the highest-value contracts from sponsors advancing programs through clinical development toward commercial launch.”
What this means for pharmaceutical and biotechnology buyers
- Assess manufacturing capabilities before selecting a CDMO. Evaluate anaerobic production infrastructure, GMP processes, strain-handling experience, analytical testing capabilities and the ability to maintain microbial viability through formulation and distribution. These factors address the capacity and quality constraints identified by Fact.MR.
- Match manufacturing commitments to clinical milestones. Early-stage programs carry attrition risk. Buyers should align capacity reservations, development spending and scale-up commitments with program progression to avoid committing to commercial-scale production before demand is sufficiently established.
- Evaluate suppliers against future product complexity. Multi-strain consortium products can require more complex manufacturing processes and analytical testing. Buyers should assess whether prospective partners can accommodate those requirements as programs advance, while reviewing relevant regulatory experience and the suitability of proposed manufacturing locations.
Report coverage
Fact.MR’s Live Biotherapeutic Products & Microbiome CDMO Market Analysis and Forecast examines global and regional market opportunities, country growth forecasts, manufacturing constraints, demand drivers and competitive positioning from 2026 to 2036.
Explore More Related Studies Published by Fact.MR Research
About Fact.MR
Fact.MR is a market research and consulting firm providing syndicated research, customized research, investment research, and market intelligence across a broad range of industries. Its research coverage includes food and beverage, healthcare, pharmaceuticals, biotechnology, consumer products, chemicals and materials, technology, industrial goods, and packaging.
Fact.MR provides market intelligence designed to help organizations understand market dynamics, emerging opportunities, competitive developments, and changing industry requirements.
Media Contact
Fact.MR
Email: [email protected]
Phone: +1 (628) 251-1583
Website: www.factmr.com
